The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Combination therapy in the treatment of hypertension
Open accessAbstract
Hypertension is a major preventable risk factor for atherosclerosis and ischemic heart disease. Although modern and effective antihypertensive drugs are available, most patients remain with a suboptimal blood pressure control. Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals - recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets. In this review, we analyse the latest information available regarding the treatment of hypertension with combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775 · cited 1×
“Reinforcing the above, a meta-analysis published in 2009 showed that patients receiving more antihypertensive drugs achieved (as expected) lower blood pressure figures and had greater reductions in the appearance of cardiovascular and cerebrovascular events [13].”
ResultBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.038 · Cited by 938
Poulter, N. R., Wedel, H., Dahlöf, B., Sever, P. S., Beevers, D. G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67186-3 · Cited by 319
Cited by
Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety
Shaito, A., Thuan, D. T. B., Phu, H. T., Nguyen, T. H. D., Hasan, H., Halabi, S., Abdelhady, S., Nasrallah, G. K., Eid, A. H., & Pintus, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00422 · Cited by 437
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Das, D., Shruthi, N. R., Banerjee, A., Jothimani, G., Duttaroy, A. K., & Pathak, S. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1221438 · Cited by 90
“However, the most effective drug has yet to be fully resolved (50).”
BackgroundNaude, J., Zentner, A., Suresh, P., Bittman, J., & Khan, N. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01526-2 · Cited by 13
Retracted
Metadata
- Authors
- Guerrero-García, C., & Rubio-Guerra, F.
- Venue
- Drugs in Context
- Publisher
- BioExcel
- Published
- 2018-06-06
- Volume
- 7
- Pages
- 1-9
- ISSN
- 1740-4398 (ISSN-L)
- OpenAlex
- W2805253551
- Cited by
- 207
- References
- 6
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.